To assess the clinical impact of NGS-based CF carrier screening, weused the following hypothetical: “If Foresight patients had received morelimited CF screening, how many missed cases would result?” For this analysis, wecompared three levels of CF screening in both the ARC cohort and in a modeled USpopulation: CF23 genotyping (“CF23”), CF sequencing without CNV analysis(“NGS”), and CF sequencing with CNV analysis (“NGS + CNV”). Here, CFTR is linked to cystic fibrosis.